Session

Predictive and prognostic factors in RCC

Poster Session 48

  • Location:
    Room 7, Capital suite (level 3)
  • Chairs:
     A. Mattei, Luzern (CH)
     M. Oya, Tokyo (JP)
     B. Peyronnet, Rennes (FR)
  • Aims and objectives of this session

    To discuss various predictive and prognostic factors in RCC.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
640
Predictive factor of lymph node metastases in patients with non-metastatic renal cell carcinoma; multi-center study

By: Kim K.S.1, Kim H.W.2, Kim J.C.3, Kwak C.4, Kim Y-J.5, Kang S.H.6, Byun S-S.7, Kim S.H.1, Hong S-H.8

Institutes: 1Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Dept. of Urology, Incheon, South Korea, 2St. Paul’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Dept. of Urology, Seoul, South Korea, 3Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea., Dept. of Urology, Bucheon, South Korea, 4Seoul National University College of Medicine, Seoul, Korea, Dept. of Urology, Seoul, South Korea, 5Chungbuk National University College of Medicine, Cheongju, Korea, Dept. of Urology, Cheongju, South Korea, 6Korea University School of Medicine, Seoul, Korea, Dept. of Urology, Seoul, South Korea, 7Seoul National University Bundang Hospital, Seongnam, Korea, Dept. of Urology, Seongnam, South Korea, 8College of Medicine, The Catholic University of Korea, Seoul, Korea, Dept. of Urology, Seoul, South Korea

641
Long-term assessment of mortality patterns after surgical treatment for non-metastatic kidney cancer: A competing risk analysis

By: Larcher A.1, Muttin F.1, Nini A.1, Trevisani F.1, Ripa F.1, Cianflone F.1, Carenzi C.1, Dell’Oglio P.1, Rigatti P.2, Dehó F.1, Montorsi F.1, Capitanio U.1, Bertini R.1

Institutes: 1IRCCS Ospedale San Raffaele, Urological Research Institute, Division of Oncology, Unit of Urology, Milan, Italy, 2Scientific Institute Istituto Auxologico Italiano, Department of Urology, Advanced Urotechnology Center, Milan, Italy

642
External validation of the Mayo Clinic Stage, Size, Grade, and Necrosis score in patients with renal cell carcinoma and venous tumor thrombus

By: Lorentz C.1, Tai C.2, Capitanio U.3, Carballido J.4, Ciancio G.5, Daneshmand S.6, Evans C.7, Gontero P.8, Haferkamp A.9, Hohenfellner M.10, Huang W.11, Espinós E.12, Martínez-Salamanca J.4, McKiernan J.13, Montorsi F.3, Pahernik S.10, Palou J.14, Pruthi R.15, Russo P.16, Scherr D.17, Spahn M.18, Terrone C.19, Tilki D.7, Donoso C.20, Vergho D.18, Wallen E.15, Zigeuner R.21, Libertino J.22, Master V.1

Institutes: 1Emory University School of Medicine, Dept. of Urology, Atlanta, United States of America, 2University of California, Dept. of Epidemiology and Biostatistics, San Francisco, United States of America, 3University Vita-Salute, Dept. of Urology, Milan, Italy, 4Universidad Autónoma De Madrid, Dept. of Urology, Madrid, Spain, 5University of Miami, Dept. of Urology, Miami, United States of America, 6University of Southern California, Dept. of Urology, Los Angeles, United States of America, 7University of California-Davis, Dept. of Urology, Sacramento, United States of America, 8University of Turin, Dept. of Urology, Turin, Italy, 9University of Frankfurt, Dept. of Urology, Frankfurt, Germany, 10University of Heidelberg, Dept. of Urology, Heidelberg, Germany, 11New York University School of Medicine, Dept. of Urology, New York, United States of America, 12Hospital Universitario Infanta Sofía, Dept. of Urology, Madrid, Spain, 13Columbia University College of Physicians and Surgeons, Dept. of Urology, New York, United States of America, 14Fundació Puigvert, Dept. of Urology, Barcelona, Spain, 15University of North Carolina, Dept. of Urology, Chapel Hill, United States of America, 16Memoria Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America, 17Weill Cornell Medical Center, Dept. of Urology, New York, United States of America, 18University of Würzburg, Dept. of Urology, Würzburg, Germany, 19University of Eastern Piedmont, Dept. of Urology, Novara, Italy, 20Hospital Universitario Y Politécnico La Fe, Dept. of Urology, Valencia, Spain, 21Medical University of Graz, Dept. of Urology, Graz, Austria, 22Lahey Clinic, Dept. of Urology, Burlington, United States of America

643
The prevalence of renal cancer detected by abdominal ultrasonography in asymptomatic individuals: A systematic review and meta-analysis to inform the case for a screening study

By: Rossi S.1, Hsu R.1, Blick C.2, Goh V.3, Hanbury D.4, Nathan P.5, Nicol D.6, Fleming S.7, Sweeting M.8, Watson C.9, Wilson E.10, Stewart G.1

Institutes: 1Addenbrooke’s Hospital, Dept. of Urology, Cambridge, United Kingdom, 2Royal Berkshire Hospital, Dept. of Urology, Reading, United Kingdom, 3Guy’s & St Thomas’ Hospitals NHS Trust, Dept. of Radiology, London, United Kingdom, 4Lister Hospital, Dept. of Urology, Stevenage, United Kingdom, 5Mount Vernon Cancer Centre, Dept. of Oncology, Northwood, United Kingdom, 6Royal Marsden Hospital, Dept. of Urology, London, United Kingdom, 7Ninewells Hospital, Centre for Forensic and Legal Medicine, Dundee, United Kingdom, 8University of Cambridge, Dept. of Public Health and Primary Care, Cambridge, United Kingdom, 9National Cancer Research Institute, Renal and Bladder Cancer Clinical Studies Group, London, United Kingdom, 10University of Cambridge, Cambridge Centre for Health Services Research, Cambridge, United Kingdom

644
Predictive and prognostic effect of inflammatory lymphadenopathies in renal cell carcinoma

By: Pecoraro A.1, Larcher A.1, Nini A.1, Muttin F.1, Stabile A.1, Di Trapani E.1, Carenzi C.1, Trevisani F.1, De Cobelli F.2, Gaboardi F.1, Guazzoni G.3, Briganti A.1, Montorsi F.1, Bertini R.1, Capitanio U.1

Institutes: 1IRCCS Ospedale San Raffaele, Urological Research Institute, Dept. of Oncology and Urology, Milan, Italy, 2IRCCS Ospedale San Raffaele, Dept. of Radiology, Milan, Italy, 3Humanitas Clinical and Research Centre, Dept. of Urology, Milan, Italy

645
Prognostic significance of Fuhrman grade and age for cancer-specific and overall survival in patients with papillary renal cell carcinoma: Results of an international multi-institutional study on 2189 patients

By: Scavuzzo A.4, Wolff I.5, Jimenez Rios M.A.4, Capitanio U.6, Dell’Oglio P.6, Krabbe L-M.7, Herrmann E.7, Klatte T.3, Shariat S.3, Borgmann H.1, Haferkamp A.1, Ecke T.8, Vergho D.9, Riedmiller H.9, Wagener N.10, Huck N.10, Pahernik S.11, Zastrow S.12, Wirth M.12, Musquera M.2, Surcel C.13, Mirvald C.13, Kalusova K.14, Hutterer G.15, Zigeuner R.15, May M.16, Gilfrich C.16, Stief C.G.17, Brookman-May S.17

Institutes: 1University Hospital Mainz, Dept. of Urology, Mainz, Germany, 2University Hospital Barcelona, Dept. of Urology, Barcelona, Spain, 3Medical University of Vienna, Dept. of Urology, Vienna, Austria, 4Instituto Nacional De Cancerologia, Dept. of Urology, Mexico, Mexico, 5Carl–Thiem–Klinikum Cottbus, Dept. of Urology, Cottbus, Germany, 6Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, 7University of Muenster Medical Center, Dept. of Urology, Muenster, Germany, 8Hospital Bad Saarow, Dept. of Urology, Bad Saarow, Germany, 9Julius–Maximilians–University Medical Centre of Würzburg, Dept. of Urology, Wurzburg, Germany, 10University Hospital Mannheim, Dept. of Urology, Mannheim, Germany, 11University Hospital Heidelberg, Dept. of Urology, Heidelberg, Germany, 12University Hospital Carl Gustav Carus, Dept. of Urology, Dresden, Germany, 13Fundeni Clinical Institute, Centre of Urological Surgery, Dialysis and Renal Transplantation, Bucharest, Romania, 14Charles University In Pilsen, Dept. of Urology, Pilsen, Czech Republic, 15Medical University Graz, Dept. of Urology, Graz, Austria, 16Klinikum St. Elisabeth Straubing, Dept. of Urology, Straubing, Germany, 17Ludwig–Maximilians–University, Dept. of Urology, Munich, Germany

646
Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease

By: Wagener N.1, Edelmann D.2, Benner A.2, Huck N.1, Hutterer G.3, Zigeuner R.3, Borgmann H.4, Haferkamp A.4, Pahernik S.5, Wolff I.6, Krabbe L.M.7, Herrmann E.7, Vergho D.8, Mirvald C.9, Surcel C.9, Musquera M.10, Ecke T.11, Prochazkova K.12, Scavuzzo A.13, Dell’Oglio P.14, Capitanio U.14, Klatte T.15, Shariat S.15, Zastrow S.16, Wirth M.16, Cindolo L.17, May M.18, Gilfrich C.18, Stief C.19, Brookman-May S.D.19

Institutes: 1Mannheim Medical Center, University of Heidelberg, Germany, Dept. of Urology, Mannheim, Germany, 2German Cancer Research Center, Heidelberg, Germany, Dept. of Biostatistics, Heidelberg, Germany, 3Medical University of Graz, Austria, Dept. of Urology, Graz, Austria, 4University Medical Center, University of Mainz, Germany, Dept. of Urology, Mainz, Germany, 5Klinikum Nuernberg, University Hospital Paracelsus University, Nuernberg, Germany, Dept. of Urology, Nuernberg, Germany, 6Carl-Thiem-Klinikum Cottbus, Germany, Dept. of Urology, Cottbus, Germany, 7University of Muenster Medical Center, Muenster, Germany, Dept. of Urology, Muenster, Germany, 8Julius-Maximilians-University Medical Center Wuerzburg, Germany, Dept. of Urology, Wuerzburg, Germany, 9Fundeni Clinical Institute, Bucharest, Romania, Center of Urological Surgery, Dialysis and Renal Transplantation, Bucharest, Romania, 10Hospital Clinic, University of Barcelona, Spain, Dept. of Urology, Barcelona, Spain, 11HELIOS Hospital, Bad Saarow, Germany, Dept. of Urology, Bad Saarow, Germany, 12Faculty Hospital Plzen and Faculty of Medicine Plzen, Charles University, Prague, Czech Republic, Dept. of Urology, Prague, Czech Republic, 13Instituto Nacional De Cancerologia (INCan), Mexico City, Mexico, Dept. of Urology, Mexico City, Mexico, 14San Rafaele Scientific Institute, Milan, Italy, Unit of Urology and Division of Experimental Oncology, Urological Research Institute (URI), Milan, Italy, 15Medical University of Vienna, Austria, Dept. of Urology, Vienna, Austria, 16University Hospital Carl Gustav Carus, Technical University of Dresden, Germany, Dept. of Urology, Dresden, Germany, 17San Pio Da Pietrelcina Hospital, Vasto, Italy, Dept. of Urology, Vasto, Italy, 18St. Elisabeth-Hospital Straubing, Germany, Dept. of Urology, Straubing, Germany, 19Ludwig-Maximilians-University, Munich, Germany, Dept. of Urology, Munich, Germany

647
Non-metastatic renal cell carcinoma follow-up, recurrences and outcomes – a RECUR database analysis

By: Dabestani S.1, Beisland C.2, Gudmundsson E.3, Stewart G.4, Lam T.5, Gietzmann W.6, Zakikhani P.6, Marconi L.7, Williams S.13, Powles T.8, Van Werkhoven E.9, Meijer R.P.12, Ljungberg B.11, Bex A.10

Institutes: 1Lund University, Dept. of Clinical Sciences, Malmö, Sweden, 2Haukeland University Hospital, Dept. of Urology, Bergen, Norway, 3Landspitali University Hospital, Dept. of Urology, Reykjavik, Iceland, 4University of Cambridge, Academic Urology Group, Cambridge, United Kingdom, 5University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom, 6Aberdeen Royal Infirmary, Dept. of Urology, Aberdeen, United Kingdom, 7Coimbra University Hospital, Dept. of Urology, Coimbra, Portugal, 8Queen Mary University of London, Barts Cancer Institute, London, United Kingdom, 9The Netherlands Cancer Institute, Dept. of Bioinformatics and Statistics, Amsterdam, The Netherlands, 10The Netherlands Cancer Institute, Division of Surgical Oncology, Department of Urology, Amsterdam, The Netherlands, 11Umeå University, Dept. of Surgical and Perioperative Sciences, Umeå, Sweden, 12University Medical Center Utrecht, Dept. of Urology, Utrecht, The Netherlands, 13University of Edinburgh, Dept. of Urology, Edinburgh, United Kingdom

648
Contemporary incidence and epidemiologic trends of brain metastases at renal cell carcinoma diagnosis

By: Gild P.1, Von Landenberg N.1, Sun M.1, Develasco G.2, Brastianos P.3, Menon M.4, Fisch M.5, Chun F.5, Nguyen P.6, Trinh Q-D.1, Choueiri T.2

Institutes: 1Brigham and Women’s Hospital, Center For Surgery and Public Health and Division of Urologic Surgery, Boston, United States of America, 2Dana-Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America, 3Dana-Farber Cancer Institute, Dept. of Cancer Biology, Boston, United States of America, 4Henry Ford Hospital, VUI Center For Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Detroit, United States of America, 5University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 6Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Dept. of Medical Oncology, Boston, United States of America

649
Utilization and outcomes of T2 partial nephrectomy: A US population based analysis of the national cancer database

By: Hamilton Z., Fero K., Bloch A., Field C., Han D., Derweesh I.

Institutes: Moores Cancer Center, Dept. of Urology, La Jolla, United States of America

650
Contact with renal sinus is a significant risk factor for metastasis in pT1 clear cell renal cell carcinoma

By: Izumi K.1, Saito K.1, Nakayama T.1, Fukuda S.2, Fukushima H.3, Uehara S.4, Koga F.3, Yonese J.4, Kageyama Y.2, Kihara K.5, Fujii Y.5

Institutes: 1Tokyo Medical And Dental Graduate School, Dept. of Urology, Tokyo, Japan, 2Saitama Cancer Center, Dept. of Urology, Saitama, Japan, 3Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Dept. of Urology, Tokyo, Japan, 4Cancer Institute Hospital, Dept. of Urology, Tokyo, Japan, 5Tokyo Medical and Dental Graduate School, Dept. of Urology, Tokyo, Japan

651
Utility of chest x-ray in follow-up of pT1 renal cell carcinoma

By: Rizzo M.1, Umari P.1, Pavan N.1, Liguori G.1, Verzotti E.1, Cancellieri L.1, Mottrie A.2, Minervini A.3, Trombetta C.3

Institutes: 1Cattinara Hospital; University of Trieste, Dept. of Urology, Trieste, Italy, 2Onze-Lieve-Vrouwziekenhuis, Dept. of Urology, Aalst, Belgium, 3University Hospital Careggi, Dept. of Urology, Florence, Italy

652
Organ confined renal cell carcinoma - are the current guidelines sufficient?

By: Frees S.1, Kamal M.1, Nestler S.2, Bidnur S.3, Levien P.1, Neisius A.1, Jaeger W.1, Thomas C.1, Thüroff J.4, Roos F.1

Institutes: 1University Medical Center, Dept. of Urology, Mainz, Germany, 2Hochtaunus Hospital Bad Homburg, Dept. of Urology, Bad Homburg, Germany, 3Vancouver Prostate Center, Dept. of Urology, Vancouver, Canada, 4University Medical Center, Dept. of Urology, Mannheim, Germany

653
Impact of hospital volume and surgeon volume on robot-assisted partial nephrectomy results: A multicenter study

By: Tondut L.1, Peyronnet B.1, Bernhard J-C.2, Vaessen C.3, Doumerc N.4, Sebe P.5, Pradere B.6, Guillonneau B.5, Nouhaud F.X.7, Brichart N.8, Alimi Q.1, Beauval J-B.4, Rammal A.9, De La Taille A.10, Baumert H.11, Droupy S.12, Bruyere F.6, Roupret M.3, Mejean A.13, Bensalah K.1

Institutes: 1CHU Rennes, Dept. of Urology, Rennes, France, 2CHU Bordeaux, Dept. of Urology, Bordeaux, France, 3CHU La Pitié Salpêtrière, Dept. of Urology, Paris, France, 4CHU Rangueil, Dept. of Urology, Toulouse, France, 5Groupe Hospitalier Privé Les Diaconesses, Dept. of Urology, Paris, France, 6CHU Tours, Dept. of Urology, Tours, France, 7CHU Rouen, Dept. of Urology, Rouen, France, 8CH Orleans, Dept. of Urology, Orléans, France, 9CH Orléans, Dept. of Urology, Orléans, France, 10CHU Henri Mondor, Dept. of Urology, Créteil, France, 11Groupe Hospitalier Privé Saint Joseph, Dept. of Urology, Paris, France, 12CHU Nîmes, Dept. of Urology, Nîmes, France, 13Hôpital Européen Georges Pompidou, Dept. of Urology, Paris, France

654
Hospital activity and costs following partial nephrectomy: A comparison of surgical modalities using UK data

By: Camp C.1, O’Hara J.1, Hughes D.1, Adshead J.2

Institutes: 1Hcd Economics, Dept. of Economics, Daresbury, United Kingdom, 2Hertfordshire and Bedfordshire Urological Cancer Centre, Lister Hospital, Dept. of Urology, Stevenage, United Kingdom